Monthly Archives: July 2011

Celebrating 1H2011′s New Drug Approvals (sort of)
July 27, 2011

The FDA approved 20 new molecular entity NDAs in the first half of 2011, which is an impressive count.  Of the 20, eighteen are new therapeutics (two were diagnostic reagents).  This number of approvals is exciting, especially since in 2011

Leave a comment

Change Starts at the Top: Imperative to Bring Biotech Voices to Pharma Boardrooms
July 19, 2011

Most of Big Pharma have been trying to reinvent themselves as nimble Biotechs, at least in the eyes of Wall Street, in order to be perceived as being innovative R&D-driven companies.    Despite the restructurings, Big Pharma is struggling with that

9 Comments

Life Sciences: The Rodney Dangerfield of Venture Capital
July 11, 2011

Note to Readers: This blog post was co-written by Bruce Booth and Bijan Salehizadeh, who co-authored an article in the July 2011 issue of Nature Biotechnology, detailing the differences in returns between Life Sciences and Tech investing. Most venture capitalists think that

27 Comments

Biotech executive’s pay premium vs Tech: more cash, less equity
July 5, 2011

Compensation in startups is a subject where vague notions of the right comparable benchmarks (“the market rate”) and organizational inertia (“that’s what we’ve done before…”) come together to prevent useful transparency. Mountains of data are thrown at comp committees to

6 Comments